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Breast cancer is the most frequently diagnosed cancer
entity and the leading cause of cancer death in females
worldwide, accounting for 23% of the total new cancer
cases and 14% of the total cancer deaths in 2008 [1].
Recently, prophylactic mastectomy in patients with
family history for breast cancer or patients with BRCA1
or BRCA2 mutations became a widely discussed topic
due to the wide media presence of celebrities under-
going this procedure. Prophylactic mastectomy in
patients with BRCA 1/2 mutations reduces the risk for
breast cancer by approximately 90%. Nevertheless,
young patients undergoing this risk reducing surgery
carry many fears and psychological stress by feeling less
female and are faced by a life-changing decision. In
addition, several studies demonstrated that not all
patients with a breast cancer history do really benefit
from prophylactic surgery of the contralateral breast
that trigger controversial discussions regarding opti-
mized breast cancer management [2].
Economic burden of breast cancer management are
permanently increasing negatively impacting the health-
care budgets. In the actual context of extensive debates
concerning increasing costs of medical services and lim-
ited resources to cover healthcare costs, new strategies
needs to be applied to more effective breast cancer man-
agement. To give an example, in the USA the costs for
prescriptions against breast cancer are the second lar-
gest category of all pharmaceutical sales with enor-
mously increasing rates. The therapy costs for each
patient with metastatic breast cancer have been reported
to be $128.556 over a mean follow-up time of 18
month. But also the trend towards the detection of ear-
lier breast cancer stages is under discussion regarding
treatment savings. The savings of costs for treatment
and palliative care in advanced breast cancer may be
counterbalanced by the high costs of more aggressive
initial treatments and longer follow-up.
Currently applied screening strategies lack sufficient
benefits and, therefore, also become disputed. The diag-
nosis of breast cancer in early stages has been shown to
improve the prognosis and consecutively reduce mortal-
ity of breast cancer patients. The recommended screen-
ing by clinical breast examination and mammography is
able to detect breast cancer in early stages and has been
shown to reduce mortality. Nevertheless, this screening
procedures cause high percentages of false-negative and
false-positive results that lead to both underdiagnosis
and overdiagnosis respectively [3]. Furthermore, estab-
lished mammography screening programs are restricted
to certain age-groups (50-69 years) and specialized
screening units and not feasible in most economically
developing countries.
Recommendations
Based on the enormous amount of health care costs for
breast cancer screening, therapy costs as well as the eco-
nomic burden of this disease, predictive medicine could be
an innovative approach towards a new era in breast cancer
prevention. Breast cancer risk assessment aims at detec-
tion of pre-malignant stages that will revolutionise breast
cancer management in patients without family history as
well as in women with hereditary disease. Innovative
approaches proposed by the PPPM paradigm promote
economically more attractive scenario for the investment
in healthcare sector, however, should get carefully analysed
through well designed pilot projects [4,5].
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